Sofwave to Participate in 10th Annual Needham Virtual MedTech & Diagnostics Conference

Sofwave Medical Ltd, an innovative player in the field of non-invasive aesthetic medical devices, has announced its participation in the 10th Annual Needham Virtual MedTech & Diagnostics Conference scheduled for August 11-12, 2025. Louis Scafuri, the Company’s CEO, and Assaf Korner, CFO, will represent Sofwave at this significant event, which brings together key stakeholders in the medical technology and diagnostics sectors.

Sofwave is recognized for its proprietary technology, SUPERB™ (Synchronous Ultrasound Parallel Beam technology), which is FDA-cleared for a variety of aesthetic applications. The technology is designed to reduce wrinkles, lift eyebrows, and improve the overall laxity of skin in several areas, including beneath the chin and on the upper arms. Additionally, Sofwave’s products are effective in the short-term treatment of cellulite and acne scars, delivering safe and effective skin improvement solutions for practitioners.

The company's extensive portfolio includes the Pure Impact™ module, which utilizes fourth-generation EMS technology cleared for muscle toning. This innovative approach not only enhances the aesthetic outcomes for patients but also simplifies the treatment process for physicians, making Sofwave a preferred choice in the medical aesthetic market.

The participation of Sofwave in the Needham Conference underscores its growing influence and commitment to advancing non-invasive aesthetic treatments. It also provides a platform for engaging with investors and industry leaders, fostering insights that could propel further advancements in aesthetic medical technology. For further inquiries, interested parties can contact Sofwave via email or reach out to Brian Ritchie at LifeSci Advisors.

Sofwave Medical Ltd. (TASE: SOFW) is positioning itself as a noteworthy player in the non-invasive aesthetic device market, particularly with its proprietary SUPERB™ technology. The upcoming participation in the 10th Annual Needham Virtual MedTech & Diagnostics Conference on August 11 - 12, 2025, is a strategic move designed to boost visibility and engage potential investors and key market players. This conference presents an opportunity for Sofwave's leadership, including CEO Louis Scafuri and CFO Assaf Korner, to showcase their innovative offerings and articulate growth strategies.

Investors should note that Sofwave's competitive advantages, such as FDA-clearance for various applications including wrinkle reduction, muscle toning, and cellulite treatment, underline its technological edge in a rapidly evolving industry. The aesthetic medical device sector is projected to grow significantly as consumer demand for non-invasive beauty treatments continues to rise. Therefore, Sofwave's ability to precisely target different skin concerns positions it well to capture market share.

Moreover, Sofwave’s focus on safety and efficacy enhances its appeal to practitioners, which is crucial in this industry where regulatory compliance and patient outcomes are paramount. Their smart design and practicality further facilitate adoption among physicians, which bodes well for revenue growth.

For potential investors, the upcoming conference is a critical watchpoint. Pay close attention to the company's forward-looking strategies and any insights shared by its executives related to market expansion, revenue projections, and product pipeline developments. Engaging with the management team will provide deeper insights into Sofwave's long-term outlook and market positioning.

In summary, considering Sofwave's innovative technology, FDA approvals, and participation in high-profile events, it presents a promising investment opportunity for those interested in the burgeoning aesthetic medical device market. Monitor post-conference announcements for potential price movements and growth metrics.